Fig. 7
From: A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors
PD-L1 expression in GCs, and estimation of responders to immune checkpoint inhibitors and mTOR inhibitors in patients with various GCs. a Light micrographs showing PD-L1 expressions in intestinal- and diffuse-type GCs. An area shown by a square in the diffuse-type GC is enlarged on the right. b The relationship between PD-L1 and mTOR expressions in diffuse-type GCs. A significant difference was found between PD-L1-positive and -negative patients on the expression of mTOR. *** P < 0.001 by Chi-square test between two populations. c The ratio of PD-L1-positive cells in whole (attached + easily-detached), attached, and easily-detached cell fractions in HGC-3 and -20 cells. Percentages of PD-L1-positive cells in the rectangle in the left figures were determined, and compared. Mean ± SD of five independent experiments. * P < 0.05 by two sample t-test. d Estimation of responders to immune checkpoint inhibitors and mTOR inhibitors in patients with various GCs. Since all PIK3CA mutated GCs were EBV or MSI subtypes in TCGA cohort, and all patients with EBV or MSI subtype GC were responders to checkpoint inhibitors, all responders to mTOR inhibitors were responders to checkpoint inhibitors